Drug Discovery Outsourcing Market Report
Drug Discovery Outsourcing Market Size By Drug Type (Small and Large Molecules), By Therapeutic Area (Respiratory System, Oncology, Immunomodulation, and Others), By Workflow (Target Identification & Screening, Target Validation & Functional Informatics, Lead Identification & Candidate Optimization, and Others), Regions, Segmentation, and forecast till 2029.
The market has been studied for the below-mentioned segmentation and
regional analysis for North America, Europe, Asia, South America, and Middle
East and Africa. These are the key regions where the Drug
Discovery Outsourcing market is operating currently and is predicted to
expand shortly. The manufacturers and suppliers involved in the Drug
Discovery Outsourcing treatment market are present across various countries
in the regions mentioned above.
Get Sample Copy of This Report @ https://greyviews.com/reports/drug-discovery-outsourcing-market/173/request-sample
The report provides a detailed understanding of the market segments
formed by combining different prospects such as drug type, therapeutic area,
workflow, and others. The key driving factors, restraints, potential growth
opportunities, and market challenges are also discussed in the paragraphs
below.
The significant players operating in the global Drug
Discovery Outsourcing market are
Merck KGaA, Wincoat Colours and Coatings Pvt. Ltd., DuPont, BASF Corporation,
BPSI Holdings LLC (Colorcon), Corel Pharma Chem., Eastman Chemical Company,
Evonik Industries AG, Roquette Freres, Sensient Technologies Corporation,
Kerry, JRS Pharma, and among others.
To achieve a substantial market share in the worldwide Drug Discovery
Outsourcing market and strengthen their position, manufacturers are pursuing
expansion methods such as current developments, mergers and acquisitions,
product innovations, collaborations, and partnerships, joint ventures.
The pharmaceutical industry is facing a number
of difficulties, including rising drug development costs, increased generic
competition, investors' expectations for double-digit growth, stricter
responses to consumer and payor complaints about high drug prices (including
from the federal government), and a lower-than-expected rate of new drugs
entering the market each year. Players can focus on their core competencies by
segmenting the various stages of drug discovery, including hit confirmation,
lead generation, lead optimization, and high-speed screening. Contract Research
Organizations (CROs) will have opportunities due to the estimated 75.0% to
80.0% of R&D spending in the biopharmaceutical industry that can be
outsourced, which is expected to accelerate market growth. Pharmaceutical
companies are partnering with manufacturing facilities in developing countries,
backed by skilled manpower, low cost, and quality data. Cost-cutting, chasing
innovation, gaining access to specialized knowledge and technology, and
increasing speed and agility are some significant factors encouraging pharma
companies to expand the level of outsourcing. Moreover, the development and
testing phases of the drug pipeline are no stranger to outsourcing solutions.
Contract research is a maturing industry sector, and there are more than 1,000
CROs in the U.S. and Europe. The top 10 accounts for approximately 40% of
industry sales. However, CROs have been focused on drug development and
clinical trial support, where they can effectively speed drugs to market.
Earlier stages of the pipeline—drug discovery and various preclinical
development tasks—have not traditionally been outsourced. This is changing.
Enquiry Before Buying This Report
@ https://greyviews.com/inquiry/173
Scope of Drug Discovery Outsourcing
Market Report
|
Report Metric |
Information |
|
Study Period |
2021-2029 |
|
Base Year |
2021 |
|
Forecast Period |
2022-2029 |
|
Market Share Unit |
USD
Billion |
|
Segments Covered |
By Drug Type, By Therapeutic Area, By Workflow, By Region |
|
Regions Covered |
North
America, Europe, Asia-Pacific, South America and Middle-East and Africa |
|
Major Players |
Merck
KGaA, Wincoat Colours and Coatings Pvt. Ltd., DuPont, BASF Corporation, BPSI
Holdings LLC (Colorcon), Corel Pharma Chem., Eastman Chemical Company, Evonik
Industries AG, Roquette Freres, Sensient Technologies Corporation, Kerry, JRS
Pharma, among
others |
Segmentation Analysis
The small molecules segment is expected to be the fastest-growing
segment in 2021.
The drug type includes small and large molecules. During the forecast
period, the small molecules segment is anticipated to grow the fastest. Small
molecules can potentially be very important and effective components in the
pharmaceutical repertoire. As a result, the small molecules market category had
the biggest market share. Additionally, small molecule benefits over larger
compounds have increased funding for the field, particularly cancer research.
Small molecules are more affordable, simpler to produce, and can be coupled
with intracellular targets, making them ideal for oral administration,
particularly for treating chronic disorders. Ongoing research projects to look into
and create novel therapies for different indications are anticipated to impact
market growth significantly.
Lead identification & candidate optimization is expected to be the
fastest-growing segment in 2021.
The workflow includes target identification & screening, target
validation & functional informatics, lead identification & candidate
optimization, and others. The lead identification & candidate optimization
segment is expected to witness the highest CAGR during the forecast period.
Segment expansion is supported by introducing cutting-edge in silico methods to
enhance the lead identification procedure, such as Computer-Aided Drug
Discovery (CADD) and structure-based drug designs. Increased outsourcing of
lead identification services is made possible by the growing demand for
professional workers who combine knowledge of analytical chemistry, metabolism,
and computer software with the expensive expense of integrating the most
cutting-edge computing technologies.
Regional
Analysis
The regional analysis provides a detailed perception of the key
regions and the countries. Some key countries analyzed for the Drug Discovery
Outsourcing include US, Canada, Mexico, Germany, France, U.K., Italy, Spain,
Russia, China, Japan, India, Brazil, Peru, UAE, South Africa and Saudi Arabia.
●
North American region witnessed a major share.
The growth in pandemic focus and the consequent outsourcing of drug discovery
to businesses with AI technology are both factors that have contributed to the
expansion of the drug discovery outsourcing market in the area. The industry is
also fueled by larger pharmaceutical and biotechnology businesses investing
more money in R&D and their focus on reducing internal costs, which has
resulted in the outsourcing of the drug discovery process.
Country Analysis
Germany's Drug Discovery Outsourcing market size was valued at
USD 0.23 billion in 2021 and is expected to reach USD 0.36 billion by 2029, at
a CAGR of 6% from 2022 to 2029. In Germany,
investments in the pharmaceutical industry are growing. Pharmaceutical
companies that do research also supported 499 clinical projects in 2019. Pharma
R&D organizations were simultaneously working on 640 biologics, 82% of
which were Phase III assets and novel biological entities. Oncology,
immunology, and infectious diseases are given a significant emphasis in the
development of biologicals. These developments have led to a rise in the demand
for outsourcing drug discovery.
● China
China Drug Discovery
Outsourcing’s market size was valued at USD 0.30 billion in 2021 and is expected
to reach USD 0.52 billion by 2029, at a CAGR of 7.2% from 2022 to 2029. Drug
discovery outsourcing sales in China have increased as a result of changing
consumer lifestyles, rising baby gear awareness, simple accessibility, and
rising per capita income. All of them encourage parents to purchase baby gear,
regardless of cost. Additionally, with the intention of buying high-quality
products for their newborns, consumers' preferences have switched more toward
those made by organized businesses, which has boosted the industry. After the
advent of new multinational players, this industry saw significant upheaval.
● India
India's Drug Discovery
Outsourcing market size was valued at USD 0.26 billion in 2021 and is expected
to reach USD 0.43 billion by 2029, at a CAGR of 6.6% from 2022 to 2029.
The outsourcing of drug discovery to India is about to get a huge boost as
pharmaceutical corporations increase their R&D efforts with the support of
the major key players. From the perspective of market demand, factors such as
sound economic growth (and correspondingly rising per capita income), rise in
diagnosis and treatment rates, growth in chronic illnesses with changing
lifestyles as a result of economic growth, and growth in chronic ailments are
driving the growth in the pharmaceutical market which fuels the need for
outsourcing.
Covid-19 Impact
Covid-19 had a major impact on almost all industries, such as ICT,
healthcare, pharmaceutical, semiconductors, automobiles, etc. However, several
companies operating in the pharmaceutical sector have seen increased revenue
due to significant changes in consumer preferences toward better treatment.
Furthermore, the growth of this market is mainly driven owing to the
increasing research and development in the healthcare sector.
Buy Now Full Report @ https://greyviews.com/checkout/173/single_user_license
Contact Us
Rocky
Shah
GreyViews
Pune
India
Phone:
(+44) 162-237-1047
Email: sales@greyviews.com
Comments
Post a Comment